5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Risk O
of O
fluid O
and O
electrolyte O
abnormalities O
, O
arrhythmia O
, O
seizures O
, O
and O
renal O
impairment O
: O
Encourage O
adequate O
hydration O
, O
assess O
concurrent O
medications O
, O
and O
consider O
laboratory O
assessments O
prior O
to O
and O
after O
use O
( O
5.1 O
, O
5.2 O
, O
5.3 O
, O
5.4 O
) O
* O
Risks O
in O
patients O
with O
renal O
insufficiency O
or O
patients O
taking O
concomitant O
medications O
that O
affect O
renal O
function O
: O
Use O
caution O
, O
ensure O
adequate O
hydration O
and O
consider O
testing O
( O
5.3 O
) O
* O
Mucosal O
ulcerations O
: O
Consider O
potential O
for O
mucosal O
ulcerations O
when O
interpreting O
colonoscopy O
findings O
in O
patients O
with O
known O
or O
suspected O
inflammatory O
bowel O
disease O
( O
5.5 O
) O
* O
Suspected O
GI O
obstruction O
or O
perforation O
: O
Rule O
out O
diagnosis O
before O
administration O
( O
4 O
, O
5.6 O
) O
* O
Patients O
at O
risk O
for O
aspiration O
: O
Observe O
during O
administration O
( O
5.7 O
) O
* O
Not O
for O
direct O
ingestion O
: O
Dissolve O
and O
take O
with O
additional O
water O
( O
5.8 O
) O
5.1 O
Serious O
Fluid O
and O
Serum O
Chemistry O
Abnormalities O
Advise O
patients O
to O
hydrate O
adequately O
before O
, O
during O
, O
and O
after O
the O
use O
of O
Prepopik O
( O
r O
) O
. O

Use O
caution O
in O
patients O
with O
congestive B-Not_AE_Candidate
heart I-Not_AE_Candidate
failure I-Not_AE_Candidate
when O
replacing O
fluids O
. O

If O
a O
patient O
develops O
significant O
vomiting B-NonOSE_AE
or O
signs O
of O
dehydration B-NonOSE_AE
including O
signs O
of O
orthostatic B-NonOSE_AE
hypotension I-NonOSE_AE
after O
taking O
Prepopik O
( O
r O
) O
, O
consider O
performing O
post-colonoscopy O
lab O
tests O
( O
electrolytes O
, O
creatinine O
, O
and O
BUN O
) O
and O
treat O
accordingly O
. O

Approximately O
20 O
% O
of O
patients O
in O
both O
arms O
( O
Prepopik O
( O
r O
) O
, O
2L O
of O
PEG O
+ O
E O
plus O
two O
* O
5-mg O
bisacodyl O
tablets O
) O
of O
clinical O
trials O
of O
Prepopik O
( O
r O
) O
had O
orthostatic B-OSE_Labeled_AE
changes I-OSE_Labeled_AE
( O
changes O
in I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
and/or O
heart O
rate O
) O
on O
the O
day O
of O
colonoscopy O
. O

In O
clinical O
trials O
orthostatic B-NonOSE_AE
changes I-NonOSE_AE
were O
documented O
out O
to O
seven O
days O
post O
colonoscopy O
. O

[ O
see O
Adverse O
Reactions O
( O
6.1 O
, O
6.2 O
) O
] O
Fluid B-OSE_Labeled_AE
and I-OSE_Labeled_AE
electrolyte I-OSE_Labeled_AE
disturbances I-OSE_Labeled_AE
can O
lead O
to O
serious O
adverse O
events O
including O
cardiac B-OSE_Labeled_AE
arrhythmias I-OSE_Labeled_AE
or O
seizures B-OSE_Labeled_AE
and O
renal B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
. O

Fluid B-NonOSE_AE
and O
electrolyte O
abnormalities I-NonOSE_AE
should O
be O
corrected O
before O
treatment O
with O
Prepopik O
( O
r O
) O
. O

In O
addition O
, O
use O
caution O
when O
prescribing O
Prepopik O
( O
r O
) O
for O
patients O
who O
have O
conditions O
or O
who O
are O
using O
medications O
that O
increase O
the O
risk O
for O
fluid B-NonOSE_AE
and O
electrolyte O
disturbances I-NonOSE_AE
or O
that O
may O
increase O
the O
risk O
of O
adverse O
events O
of O
seizure B-NonOSE_AE
, O
arrhythmia B-NonOSE_AE
, O
and O
renal B-NonOSE_AE
impairment I-NonOSE_AE
. O

5.2 O
Seizures O
There O
have O
been O
reports O
of O
generalized B-OSE_Labeled_AE
tonic I-OSE_Labeled_AE
- I-OSE_Labeled_AE
clonic I-OSE_Labeled_AE
seizures I-OSE_Labeled_AE
with O
the O
use O
of O
bowel O
preparation O
products O
in O
patients O
with O
no O
prior O
history O
of O
seizures B-Not_AE_Candidate
. O

The O
seizure B-OSE_Labeled_AE
cases O
were O
associated O
with O
electrolyte B-OSE_Labeled_AE
abnormalities I-OSE_Labeled_AE
( O
e.g. O
, O
hyponatremia B-OSE_Labeled_AE
, O
hypokalemia B-OSE_Labeled_AE
, O
hypocalcemia B-OSE_Labeled_AE
, O
and O
hypomagnesemia B-OSE_Labeled_AE
) O
and O
low B-OSE_Labeled_AE
serum I-OSE_Labeled_AE
osmolality I-OSE_Labeled_AE
. O

The O
neurologic B-NonOSE_AE
abnormalities I-NonOSE_AE
resolved O
with O
correction O
of O
fluid B-NonOSE_AE
and O
electrolyte O
abnormalities I-NonOSE_AE
. O

Use O
caution O
when O
prescribing O
Prepopik O
( O
r O
) O
for O
patients O
with O
a O
history O
of O
seizures B-Not_AE_Candidate
and O
in O
patients O
at O
risk O
of O
seizure B-NonOSE_AE
, O
such O
as O
patients O
taking O
medications O
that O
lower B-NonOSE_AE
the I-NonOSE_AE
seizure I-NonOSE_AE
threshold I-NonOSE_AE
( O
e.g. O
, O
tricyclic O
antidepressants O
) O
, O
patients O
withdrawing O
from O
alcohol O
or O
benzodiazepines O
, O
patients O
with O
known O
or O
suspected O
hyponatremia B-Not_AE_Candidate
. O

[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O
5.3 O
Use O
in O
Patients O
with O
Renal O
Impairment O
As O
in O
other O
magnesium O
containing O
bowel O
preparations O
, O
use O
caution O
when O
prescribing O
Prepopik O
( O
r O
) O
for O
patients O
with O
impaired B-Not_AE_Candidate
renal I-Not_AE_Candidate
function I-Not_AE_Candidate
or O
patients O
taking O
concomitant O
medications O
that O
may O
affect O
renal O
function O
( O
such O
as O
diuretics O
, O
angiotensin O
converting O
enzyme O
inhibitors O
, O
angiotensin O
receptor O
blockers O
, O
or O
non-steroidal O
anti-inflammatory O
drugs O
) O
. O

These O
patients O
may O
be O
at O
increased O
risk O
for O
renal B-NonOSE_AE
injury I-NonOSE_AE
. O

Advise O
these O
patients O
of O
the O
importance O
of O
adequate O
hydration O
before O
, O
during O
and O
after O
the O
use O
of O
Prepopik O
( O
r O
) O
. O

Consider O
performing O
baseline O
and O
post-colonoscopy O
laboratory O
tests O
( O
electrolytes O
, O
creatinine O
, O
and O
BUN O
) O
in O
these O
patients O
. O

In O
patients O
with O
severely O
reduced B-Not_AE_Candidate
renal I-Not_AE_Candidate
function I-Not_AE_Candidate
( I-Not_AE_Candidate
creatinine I-Not_AE_Candidate
clearance I-Not_AE_Candidate
< I-Not_AE_Candidate
3 I-Not_AE_Candidate
0 I-Not_AE_Candidate
mL I-Not_AE_Candidate
/ I-Not_AE_Candidate
min I-Not_AE_Candidate
) O
, O
accumulation B-NonOSE_AE
of I-NonOSE_AE
magnesium I-NonOSE_AE
in I-NonOSE_AE
plasma I-NonOSE_AE
may O
occur O
. O

5.4 O
Cardiac O
Arrhythmias O
There O
have O
been O
rare O
reports O
of O
serious O
arrhythmias B-OSE_Labeled_AE
associated O
with O
the O
use O
of O
ionic O
osmotic O
laxative O
products O
for O
bowel O
preparation O
. O

Use O
caution O
when O
prescribing O
Prepopik O
( O
r O
) O
for O
patients O
at O
increased O
risk O
of O
arrhythmias B-NonOSE_AE
( O
e.g. O
, O
patients O
with O
a O
history O
of O
prolonged B-Not_AE_Candidate
QT I-Not_AE_Candidate
, O
uncontrolled O
arrhythmias B-Not_AE_Candidate
, O
recent O
myocardial B-Not_AE_Candidate
infarction I-Not_AE_Candidate
, O
unstable B-Not_AE_Candidate
angina I-Not_AE_Candidate
, O
congestive B-Not_AE_Candidate
heart I-Not_AE_Candidate
failure I-Not_AE_Candidate
, O
or O
cardiomyopathy B-Not_AE_Candidate
) O
. O

Pre-dose O
and O
post-colonoscopy O
ECGs O
should O
be O
considered O
in O
patients O
at O
increased O
risk O
of O
serious O
cardiac B-NonOSE_AE
arrhythmias I-NonOSE_AE
. O

5.5 O
Colonic O
Mucosal O
Ulceration O
, O
Ischemic O
Colitis O
and O
Ulcerative O
Colitis O
Osmotic O
laxatives O
may O
produce O
colonic B-OSE_Labeled_AE
mucosal I-OSE_Labeled_AE
aphthous I-OSE_Labeled_AE
ulcerations I-OSE_Labeled_AE
and O
there O
have O
been O
reports O
of O
more O
serious O
cases O
of O
ischemic B-OSE_Labeled_AE
colitis I-OSE_Labeled_AE
requiring O
hospitalization O
. O

Concurrent O
use O
of O
additional O
stimulant O
laxatives O
with O
Prepopik O
( O
r O
) O
may O
increase O
this O
risk O
. O

The O
potential O
for O
mucosal B-NonOSE_AE
ulcerations I-NonOSE_AE
should O
be O
considered O
when O
interpreting O
colonoscopy O
findings O
in O
patients O
with O
known O
or O
suspected O
inflammatory B-Not_AE_Candidate
bowel I-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O
5.6 O
Use O
in O
Patients O
with O
Significant O
Gastrointestinal O
Disease O
If O
gastrointestinal B-Not_AE_Candidate
obstruction I-Not_AE_Candidate
or O
perforation O
is O
suspected O
, O
perform O
appropriate O
diagnostic O
studies O
to O
rule O
out O
these O
conditions O
before O
administering O
Prepopik O
( O
r O
) O
. O

Use O
with O
caution O
in O
patients O
with O
severe O
active O
ulcerative B-Not_AE_Candidate
colitis I-Not_AE_Candidate
. O

5.7 O
Aspiration O
Patients O
with O
impaired B-Not_AE_Candidate
gag I-Not_AE_Candidate
reflex I-Not_AE_Candidate
and O
patients O
prone O
to O
regurgitation B-Not_AE_Candidate
or O
aspiration B-Not_AE_Candidate
should O
be O
observed O
during O
the O
administration O
of O
Prepopik O
( O
r O
) O
. O

Use O
with O
caution O
in O
these O
patients O
. O

5.8 O
Not O
for O
Direct O
Ingestion O
Each O
packet O
must O
be O
dissolved O
in O
5 O
ounces O
of O
cold O
water O
and O
administered O
at O
separate O
times O
according O
to O
the O
dosing O
regimen O
. O

Ingestion O
of O
additional O
water O
is O
important O
to O
patient O
tolerance O
. O

Direct O
ingestion O
of O
the O
undissolved O
powder O
may O
increase O
the O
risk O
of O
nausea B-NonOSE_AE
, O
vomiting B-NonOSE_AE
, O
dehydration B-NonOSE_AE
, O
and O
electrolyte B-NonOSE_AE
disturbances I-NonOSE_AE
. O

